Compare TALK & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | TNDM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | 598 | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.7M | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | TALK | TNDM |
|---|---|---|
| Price | $5.23 | $15.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 19 |
| Target Price | $6.42 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $26.02 | $8.11 |
| Revenue Next Year | $21.24 | $11.85 |
| P/E Ratio | $155.55 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $2.22 | $10.00 |
| 52 Week High | $5.24 | $29.65 |
| Indicator | TALK | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 44.60 |
| Support Level | $5.19 | $13.59 |
| Resistance Level | $5.23 | $16.00 |
| Average True Range (ATR) | 0.02 | 0.81 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 72.73 | 49.22 |
Talkspace Inc is a virtual behavioral healthcare company offering its members convenient and affordable access to a fully-credentialed network of qualified providers across a wide and growing spectrum of care through virtual psychotherapy and psychiatry. It is a single destination for comprehensive mental health care, including therapy for individuals, couples, and teens, as well as psychiatric treatment and medication management (18+), and self-guided tools and resources. The company's customers include Health insurance plans from commercial and government institutions, and employee assistance programs, Direct-to-Enterprise, and Individual subscribers. The company operates as a single segment.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.